
Healthcare


Acura Pharmaceuticals Announces Successful Results from Study AP-LTX-301
PALATINE, Ill., Jan 08, 2018 -Acura Pharmaceuticals, Inc. (OTC QB: ACUR), a specialty pharmaceutical company innovating abuse deterrent drugs, today announced that topline results from clinical study AP-LTX-301 (Study 301) for its LIMITx(TM) excess oral […]

Acura Pharmaceuticals, Inc (NASDAQ:ACUR) CEO Interview
Acura Pharmaceuticals, Inc (NASDAQ:ACUR)
Interview with Bob Jones, CEO […]

Fluoro Pharma Medical (OTCBB:FPMI) CEO Interview
Fluoro Pharma Medical (OTCBB:FPMI)
Interview with Thijs Spoor, CEO and Chairman […]

CardioComm Solutions (TSX.V:EKG) CEO Interview
CardioComm Solutions (TSX.V:EKG) CEO: Etienne Grima […]

StemCells, Inc (NASDAQ:STEM) CEO Interview
StemCells, Inc (NASDAQ:STEM)
Interview with Martin McGlynn, Ceo […]

REVA Medical (ASX:RVA) CEO Interview
REVA Medical (ASX:RVA)
Interview with Bob Stockman, Ceo […]

IsoRay, Inc. (AMEX: ISR) CEO Interview
IsoRay, Inc. (AMEX: ISR)
Interview with Dwight Babcock, Chairman and CEO […]

Long-Term Contract in Place for Safety Syringe Platform: Revolutions Medical
Revolutions Medical Corp (OTC BB: RMCP)
Interview with Ron Wheet, CEO […]

Cardiogenesis Corporation: Positive Results from STAR-Heart Study
Cardiogenesis Corporation (OTC QB: CGCP)
Interview with Paul J. McCormick, Executive Chairman […]